Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selatogrel self-administration for suspected recurrent acute myocardial infarction
NL-OMON54126Phase 3Recruiting
- Sponsor
- Idorsia
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Selatogrel with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started May 2022; status: recruiting.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON54126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54126.